– USA, IA – KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today the appointment of David S. Tierney, M.D. to its Board of Directors.
Dr. Tierney currently serves as President & Chief Executive Officer of Icon Bioscience, Inc., a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its patented and proprietary Verisome® drug delivery technology.
Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, “David’s track record of successfully growing multiple pharmaceutical and medical device companies and specialization in advancing companies from development stage to commercialization will be of great value to KemPharm as we prepare for the potential approval of KP201/APAP. We are very happy to add David to our Board of Directors and leverage his expertise.”
Prior to being appointed CEO of Icon Bioscience, Dr. Tierney served as President & COO of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in mid-2008. Oceana was acquired by Salix Pharmaceuticals in December 2011. In 2000, David was appointed President & CEO of Hydro Med Sciences (HMS), a specialty pharmaceutical company that he rebranded as Valera Pharmaceuticals and completed an initial public offering in 2005. Valera has since been merged into Endo Pharmaceuticals.
Prior to Valera, Dr. Tierney was President of Biovail Technologies, a drug delivery division of Biovail Corporation, a predecessor to Valeant Pharmaceuticals International. Earlier in his career, he served as Senior VP, Drug Development at Roberts Pharmaceutical and in a variety of management positions at Elan Corporation. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland.
About KemPharm
KemPharm is a specialty pharmaceutical company focused on the discovery and development of NME prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high needs areas of pain, ADHD and other CNS disorders.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
